Lung cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• EGFR 301
• PD-L1 161
• PD-1 157
• KRAS 97
• ALK 72
• TP53 10
• HER2 61
• MET 43
• STAT3 0
• PI3K 1
• AKT 2
• ROS1 27
• VEGF 23
• mTOR 0
• BRAF 9
• RET 9
• NRF2 1
• MAPK 1
• ERK 0
• STING 0
• STK11 7
• YAP 1
• DLL3 27
• CTLA-4 15
• RAS 15
• CTNNB1 0
• TROP2 12
• JAK 1
• HIF-1 1
• AMPK 0
• PARP 2
• KEAP1 5
• JNK 0
• MYC 1
• B7-H3 14
• GPX4 0
• HER3 11
• PTEN 4
• MEK 1
• TIGIT 6
• FGFR 3
• IL-6 1
• PPAR 0
• HDAC 0
• EZH2 2
• PRMT5 7
• FAK 0
• COX-2 0
• HMGB1 0
• NTRK 5
• AXL 3
• BCL-2 0
• CXCR4 1
• CD47 1
• CDK4/6 4
• METTL3 0
• NLRP3 0
• HSP90 0
• SHP2 0
• MDM2 1

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 18,106 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

  NCT05132075· Novartis Pharmaceuticals· Updated 6 Nov 2026

  “Business reasons and not based on any safety concerns.”Registry text, quoted unchanged. Source

• Suspended

  Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

  NCT05642195· National Cancer Institute (NCI)· Updated 6 Nov 2026

  “Revisions to eligibility/design being made prior to enrollment of first participants.”Registry text, quoted unchanged. Source

• Suspended

  Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

  NCT06694454· National Cancer Institute (NCI)· Updated 6 Nov 2026

  “Placed on voluntary hold to new recruitment pending modification to combination monoclonal antibody treatment.”Registry text, quoted unchanged. Source

• Terminated

  CT-95 in Advanced Cancers Associated With Mesothelin Expression

  NCT06756035· Context Therapeutics Inc.· Updated 5 Nov 2026

  “The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termination was not due to any safety or efficacy concerns.”Registry text, quoted unchanged. Source

• Terminated

  A Nutritional Supplement to Support People With Non-small Cell Lung Cancer

  NCT04175769· AHS Cancer Control Alberta· Updated 3 Nov 2026

  “Unreliable supply of investigational product.”Registry text, quoted unchanged. Source

• Withdrawn

  Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer

  NCT07353957· Genmab· Updated 2 Nov 2026

  “This study-level decision was based on the evolving treatment landscape and strategic portfolio considerations and is not related to any safety concern.”Registry text, quoted unchanged. Source

• Suspended

  HEARTS Trial for Thoracic Cancers

  NCT07132918· University of Wisconsin, Madison· Updated 30 Oct 2026

  “Funding issues”Registry text, quoted unchanged. Source

• Terminated

  A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy

  NCT04856176· Tufts Medical Center· Updated 30 Oct 2026

  “Futility”Registry text, quoted unchanged. Source

• Terminated

  PRO1107 in Patients With Advanced Solid Tumors

  NCT06171789· Genmab· Updated 29 Oct 2026

  “Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation”Registry text, quoted unchanged. Source

• Suspended

  Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

  NCT04402788· National Cancer Institute (NCI)· Updated 29 Oct 2026

  “Scheduled Interim Monitoring”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma

  NCT07902921· National Cancer Institute (NCI)· Source

• Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

  NCT05132075· Novartis Pharmaceuticals· Source

• Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

  NCT06211036· Amgen· Source

• Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

  NCT02484404· National Cancer Institute (NCI)· Source

• Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  NCT06498635· National Cancer Institute (NCI)· Source

• A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

  NCT06780085· Merck Sharp & Dohme LLC· Source

• A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

  NCT07459634· Jazz Pharmaceuticals· Source

• A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  NCT05920356· Amgen· Source

• The Vanguard Study: Testing a New Way to Screen for Cancer

  NCT06995898· National Cancer Institute (NCI)· Source

• Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

  NCT05642195· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 145
• Organoids 47
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 43
• Gene Expression Profiling 313
• Sequence Analysis, RNA 43
• Whole Genome Sequencing 13
• Exome Sequencing 18
• Proteomics 133
• Metabolomics 66
• Mass Spectrometry 25
• Flow Cytometry 73
• Immunohistochemistry 190
• Liquid Biopsy 76
• Circulating Tumor DNA 82
• Xenograft Model Antitumor Assays 615
• Positron-Emission Tomography 70
• Magnetic Resonance Imaging 115
• Machine Learning 289
• Deep Learning 209
• Cohort Studies 288
• Genome-Wide Association Study 75

• Comparison of Two Deep Learning Models and Their Combination for 1-year Lung Cancer Detection in Two Screening Cohorts.

  Radiol Cardiothorac Imaging, Dec 2026

• Multimodal Transformer Integrating CT and Pathology for Postoperative Risk Stratification in Stage I Non-Small Cell Lung Cancer.

  Radiol Imaging Cancer, Nov 2026

• Estimating heterogeneous treatment effects with survival outcomes via a deep survival learner.

  Lifetime Data Anal, Oct 2026

• External evaluation of a deep learning-based algorithm for automated lung tumor and esophagus segmentation on CBCT.

  Biomed Phys Eng Express, Oct 2026

• ReViT-RF: A hybrid ResNet-50-Vision Transformer with a Radiomic Feature Fusion framework for lung tumor classification and TNM-based stage prediction using CT images.

  PLoS One, Oct 2026

• EffAtt-LungNet: An attention-guided EfficientNet framework for three-class lung histopathology classification.

  PLoS One, Oct 2026

• Identification of YES1 Inhibitors From Approved Drugs Using a Multimodal Deep Learning Framework.

  Mol Inform, Oct 2026

• A transfer learning-based hybrid deep- and machine-learning regression approach for predicting the postoperative pulmonary function.

  Eur Radiol Exp, Sept 2026

• An end-to-end deep learning approach for lung nodule segmentation and classification using LN-DETR and deep sequential convolutional harmonic networks.

  Comput Biol Med, Sept 2026

• Differential Diagnosis of Lung Cancer Using Artificial Intelligence-Based Extracellular Vesicle Analysis: A Pilot Study.

  ACS Nano, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.